Syed Raza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Syed Raza has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
A Sotiriou
Barts Heart Centre, London, UK
1 shared publication- Amare Bitew Mekonnen
Department of Biology, College of Science, Bahir Dar University, P.O. Box 79, Bahir Dar, Ethiopia, bdu.edu.et
1 shared publication Aneesh George
Novartis Healthcare, Hyderabad, India
1 shared publicationC Hayward
Barts Health NHS Trust, London
1 shared publicationDavid Jakouloff
Health Outcomes, Bristol-Myers Squibb International, Rueil-Malmaison, France
1 shared publication- Hamza Masood
Texas A&M University School of Medicine, Bryan, TX
1 shared publication
Latest Publications
- Open Access
- 27 February 2024
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 12, 1291230
Anti-ulcerative colitis effects of chemically characterized extracts from Calliandra haematocephala in acetic acid-induced ulcerative colitis
Background: Ulcerative colitis is a chronic immune-mediated inflammatory bowel disease that involves inflammation and ulcers of the colon and rectum. To date, no definite cure for this disease is available.Objective: The objective of the current study was to assess the effect of Calliandra haematocephala on inflammatory mediators and oxidative stress markers for the exploration of its anti-ulcerative colitis activity in rat models of acetic acid-induced ulcerative colitis.Methods: Methanolic and n-hexane extracts of areal parts of the plant were prepared by cold extraction method. Phytochemical analysis of both extracts was performed by qualitative analysis, quantitative methods, and high-performance liquid chromatography (HPLC). Prednisone at 2 mg/kg dose and plant extracts at 250, 500, and 750 mg/kg doses were given to Wistar rats for 11 days, which were given acetic acid on 8th day through the trans-rectal route for the induction of ulcerative colitis. A comparison of treatment groups was done with a normal control group and a colitis control group. To evaluate the anti-ulcerative colitis activity of Calliandra haematocephala, different parameters such as colon macroscopic damage, ulcer index, oxidative stress markers, histopathological examination, and mRNA expression of pro and anti-inflammatory mediators were evaluated. mRNA expression analysis was carried out by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR).Results: The phytochemical evaluation revealed polyphenols, flavonoids, tannins, alkaloids, and sterols in both extracts of the plant. Results of the present study exhibited that both extracts attenuated the large bowel inflammation and prevented colon ulceration at all tested doses. Macroscopic damage and ulcer scoreswere significantly decreased by both extracts. Malondialdehyde (MDA) levels and nitrite/nitrate concentrations in colon tissues were returned to normal levels while superoxide dismutase (SOD) activity was significantly improved by all doses. Histopathological examination exhibited that both extracts prevented the inflammatory changes, cellular infiltration, and colon thickening. Gene expression analysis by RT-qPCR revealed the downregulation of pro-inflammatory markers such as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2) whereas the anti-inflammatory cytokines including Interleukin-4 (IL-4) and Interleukin-10 (IL-10) were found to be upregulated in treated rats.Conclusion: It was concluded based on study outcomes that methanolic and n-hexane extracts of Calliandra haematocephala exhibited anti-ulcerative colitis activity through modulation of antioxidant defense mechanisms and the immune system. In this context, C. haematocephala can be considered as a potential therapeutic approach for cure of ulcerative colitis after bioassay-directed isolation of bioactive phytochemicals and clinical evaluation.
- 27 February 2024
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 12, 1291230
Open AccessAnti-ulcerative colitis effects of chemically characterized extracts from Calliandra haematocephala in acetic acid-induced ulcerative colitis
Background: Ulcerative colitis is a chronic immune-mediated inflammatory bowel disease that involves inflammation and ulcers of the colon and rectum. To date, no definite cure for this disease is available.Objective: The objective of the current study was to assess the effect of Calliandra haematocephala on inflammatory mediators and oxidative stress markers for the exploration of its anti-ulcerative colitis activity in rat models of acetic acid-induced ulcerative colitis.Methods: Methanolic and n-hexane extracts of areal parts of the plant were prepared by cold extraction method. Phytochemical analysis of both extracts was performed by qualitative analysis, quantitative methods, and high-performance liquid chromatography (HPLC). Prednisone at 2 mg/kg dose and plant extracts at 250, 500, and 750 mg/kg doses were given to Wistar rats for 11 days, which were given acetic acid on 8th day through the trans-rectal route for the induction of ulcerative colitis. A comparison of treatment groups was done with a normal control group and a colitis control group. To evaluate the anti-ulcerative colitis activity of Calliandra haematocephala, different parameters such as colon macroscopic damage, ulcer index, oxidative stress markers, histopathological examination, and mRNA expression of pro and anti-inflammatory mediators were evaluated. mRNA expression analysis was carried out by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR).Results: The phytochemical evaluation revealed polyphenols, flavonoids, tannins, alkaloids, and sterols in both extracts of the plant. Results of the present study exhibited that both extracts attenuated the large bowel inflammation and prevented colon ulceration at all tested doses. Macroscopic damage and ulcer scoreswere significantly decreased by both extracts. Malondialdehyde (MDA) levels and nitrite/nitrate concentrations in colon tissues were returned to normal levels while superoxide dismutase (SOD) activity was significantly improved by all doses. Histopathological examination exhibited that both extracts prevented the inflammatory changes, cellular infiltration, and colon thickening. Gene expression analysis by RT-qPCR revealed the downregulation of pro-inflammatory markers such as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2) whereas the anti-inflammatory cytokines including Interleukin-4 (IL-4) and Interleukin-10 (IL-10) were found to be upregulated in treated rats.Conclusion: It was concluded based on study outcomes that methanolic and n-hexane extracts of Calliandra haematocephala exhibited anti-ulcerative colitis activity through modulation of antioxidant defense mechanisms and the immune system. In this context, C. haematocephala can be considered as a potential therapeutic approach for cure of ulcerative colitis after bioassay-directed isolation of bioactive phytochemicals and clinical evaluation.
- Open Access
- 27 October 2017
- Published by IP Innovative Publication Pvt Ltd in Panacea Journal of Medical Sciences
- Vol. 7 (3) , 121-126
Evaluation of various physiological parameters affecting the outcomes in patients underwent dialysis procedure
The kidney plays a vital role in homeostatic function by regulating the salts/water balance in the body. Renal function is compromised due to various factors internal and external conditions such as diabetic nephropathy (8.3%), hypertension (HTN) (42.2%), diabetes and hypertension (22.9%), drugs, age, and immune-related. Dialysis is the only option for end-stage renal disease (ESRD) beside kidney transplantation. This retrospective study was based on the collection of data from the profiles of patients undergoing dialysis in order to find the variations in physiological parameters such as; hemoglobin (Hb), bilirubin, serum creatinine, urea level, and blood pressure(B.P) both pre- and post-dialysis. Patients had concomitant diseases; hepatitis B virus (8.3%), hepatitis C virus (42.2%), diabetes mellitus (29.4%) and HTN (78.9%). Blood pressure was higher than the standard about 6-9mmHg systolic pre-dialysis and 10mm Hg post-dialysis. Whereas, the diastolic B.P was lower about 5mmHg pre-dialysis while it was up to the standards after dialysis. The Hb levels were within range showing the minor variation of about 0.2-0.3g/dL. Serum creatinine levels were higher 7.1985±3.26930 to7.9761±2.46952 and BUN was also higher than normal with the mean difference of about 0.2-5mg/dL. In conclusion, the blood pressure, hemoglobin, serum creatinine and blood urea nitrogen decreases which were raised earlier to dialysis. The weight of patient also decreased after dialysis. However increased in body weight have been observed in patients with kidney disease accompanied with diabetes. These parameters must be properly controlled to improve the health outcomes.
- 27 October 2017
- Published by IP Innovative Publication Pvt Ltd in Panacea Journal of Medical Sciences
- Vol. 7 (3) , 121-126
Open AccessEvaluation of various physiological parameters affecting the outcomes in patients underwent dialysis procedure
The kidney plays a vital role in homeostatic function by regulating the salts/water balance in the body. Renal function is compromised due to various factors internal and external conditions such as diabetic nephropathy (8.3%), hypertension (HTN) (42.2%), diabetes and hypertension (22.9%), drugs, age, and immune-related. Dialysis is the only option for end-stage renal disease (ESRD) beside kidney transplantation. This retrospective study was based on the collection of data from the profiles of patients undergoing dialysis in order to find the variations in physiological parameters such as; hemoglobin (Hb), bilirubin, serum creatinine, urea level, and blood pressure(B.P) both pre- and post-dialysis. Patients had concomitant diseases; hepatitis B virus (8.3%), hepatitis C virus (42.2%), diabetes mellitus (29.4%) and HTN (78.9%). Blood pressure was higher than the standard about 6-9mmHg systolic pre-dialysis and 10mm Hg post-dialysis. Whereas, the diastolic B.P was lower about 5mmHg pre-dialysis while it was up to the standards after dialysis. The Hb levels were within range showing the minor variation of about 0.2-0.3g/dL. Serum creatinine levels were higher 7.1985±3.26930 to7.9761±2.46952 and BUN was also higher than normal with the mean difference of about 0.2-5mg/dL. In conclusion, the blood pressure, hemoglobin, serum creatinine and blood urea nitrogen decreases which were raised earlier to dialysis. The weight of patient also decreased after dialysis. However increased in body weight have been observed in patients with kidney disease accompanied with diabetes. These parameters must be properly controlled to improve the health outcomes.
- Open Access
- 1 October 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (suppl_1) , i55
134Implantable cardioverter defibrillator use in octogenarians
Introduction: Implantable cardioverter-defibrillators (ICDs) have international guideline endorsement as a therapy to reduced sudden cardiac death in patients with severe systolic cardiac dysfunction. However, their role in octogenarians is uncertain. We sought to describe current practice pertaining to octogenarians and ICD implantation at a tertiary referral centre.
- 1 October 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (suppl_1) , i55
Open Access134Implantable cardioverter defibrillator use in octogenarians
Introduction: Implantable cardioverter-defibrillators (ICDs) have international guideline endorsement as a therapy to reduced sudden cardiac death in patients with severe systolic cardiac dysfunction. However, their role in octogenarians is uncertain. We sought to describe current practice pertaining to octogenarians and ICD implantation at a tertiary referral centre.
- 1 August 2017
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 23 (8) , 893-901
The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review
Formulary restrictions are implemented to reduce pharmacy costs and ensure appropriate use of pharmaceutical products. As adoption of formulary restrictions increases with rising pharmacy costs, there is a need to better understand the potential effect of formulary restrictions on patient and payer outcomes. To conduct a systematic literature review that assesses the effect of formulary restrictions on the following outcomes: medication adherence, clinical outcomes, treatment satisfaction, drug utilization, health care resource utilization, and economic outcomes. Studies published in 2005 or later were identified from the MEDLINE, Embase, and Cochrane databases and the National Health Service Economic Evaluation Database, using 2 sets of search terms. A total of 17 formulary restriction terms (e.g., step therapy [ST] and prior authorization [PA]) and 55 outcome terms were included, resulting in 935 unique search term combinations. Two reviewers independently conducted analyses of the titles, abstracts, and full-text articles. The search was limited to English-language articles that evaluated the effect of ST and/or PA placed by U.S. third-party payers on the following outcomes: patient outcomes (medication adherence, clinical outcomes, and treatment satisfaction) and payer outcomes (drug utilization, health care resource utilization, and economic outcomes). Of 2,321 reviewed articles, 59 articles met the study inclusion criteria. The included studies assessed the effect of ST (n = 18), PA (n = 35), or both (n = 6) on medication adherence (n = 14), clinical outcomes (n = 12), treatment satisfaction (n = 2), drug utilization (n = 39), health care resource utilization (n = 18), and economic outcomes (n = 42). The 59 articles measured 164 outcomes across the patient, health care resource utilization, and economic outcome categories of interest. Of the total number of outcomes, 50.6% (n = 83) were negative in direction or were unfavorable, whereas 40.2% (n = 66) were positive in direction or were favorable, when the perspectives of patients and payers were considered. Of the total number of drug utilization outcomes reported (n = 46), the majority showed lower drug utilization (> 90%). However, in some of the articles, pharmacy cost savings resulting from lower drug utilization appeared to be offset by increased medical costs. Formulary coverage decisions may have unintended consequences on patient and payer outcomes despite lower drug utilization and pharmacy cost savings; therefore, careful evaluation of restrictions before policy implementation and continued reevaluation after implementation is warranted. This study was funded by Novartis Pharmaceuticals. Park and Ko are employed by Novartis Pharmaceuticals in East Hanover, New Jersey, and Ko holds stock in Novartis. Raza, George, and Agrawal are employed by Novartis Healthcare in Hyderabad, India. Study concept and design were contributed primarily by Park and Ko, along with the other authors. Raza, George, and Agrawal collected the data, along with Park and Ko. Data interpretation was performed by Agrawal, Raza, George, Park, and Ko. The manuscript was written and revised by Raza, George, and Park, along with Ko and Agrawal. Results from this systematic literature review were presented at the AMCP Annual Meeting 2016; San Francisco, California; April 19-22, 2016.
- 1 August 2017
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 23 (8) , 893-901
The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review
Formulary restrictions are implemented to reduce pharmacy costs and ensure appropriate use of pharmaceutical products. As adoption of formulary restrictions increases with rising pharmacy costs, there is a need to better understand the potential effect of formulary restrictions on patient and payer outcomes. To conduct a systematic literature review that assesses the effect of formulary restrictions on the following outcomes: medication adherence, clinical outcomes, treatment satisfaction, drug utilization, health care resource utilization, and economic outcomes. Studies published in 2005 or later were identified from the MEDLINE, Embase, and Cochrane databases and the National Health Service Economic Evaluation Database, using 2 sets of search terms. A total of 17 formulary restriction terms (e.g., step therapy [ST] and prior authorization [PA]) and 55 outcome terms were included, resulting in 935 unique search term combinations. Two reviewers independently conducted analyses of the titles, abstracts, and full-text articles. The search was limited to English-language articles that evaluated the effect of ST and/or PA placed by U.S. third-party payers on the following outcomes: patient outcomes (medication adherence, clinical outcomes, and treatment satisfaction) and payer outcomes (drug utilization, health care resource utilization, and economic outcomes). Of 2,321 reviewed articles, 59 articles met the study inclusion criteria. The included studies assessed the effect of ST (n = 18), PA (n = 35), or both (n = 6) on medication adherence (n = 14), clinical outcomes (n = 12), treatment satisfaction (n = 2), drug utilization (n = 39), health care resource utilization (n = 18), and economic outcomes (n = 42). The 59 articles measured 164 outcomes across the patient, health care resource utilization, and economic outcome categories of interest. Of the total number of outcomes, 50.6% (n = 83) were negative in direction or were unfavorable, whereas 40.2% (n = 66) were positive in direction or were favorable, when the perspectives of patients and payers were considered. Of the total number of drug utilization outcomes reported (n = 46), the majority showed lower drug utilization (> 90%). However, in some of the articles, pharmacy cost savings resulting from lower drug utilization appeared to be offset by increased medical costs. Formulary coverage decisions may have unintended consequences on patient and payer outcomes despite lower drug utilization and pharmacy cost savings; therefore, careful evaluation of restrictions before policy implementation and continued reevaluation after implementation is warranted. This study was funded by Novartis Pharmaceuticals. Park and Ko are employed by Novartis Pharmaceuticals in East Hanover, New Jersey, and Ko holds stock in Novartis. Raza, George, and Agrawal are employed by Novartis Healthcare in Hyderabad, India. Study concept and design were contributed primarily by Park and Ko, along with the other authors. Raza, George, and Agrawal collected the data, along with Park and Ko. Data interpretation was performed by Agrawal, Raza, George, Park, and Ko. The manuscript was written and revised by Raza, George, and Park, along with Ko and Agrawal. Results from this systematic literature review were presented at the AMCP Annual Meeting 2016; San Francisco, California; April 19-22, 2016.
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Evaluation of the Impact of Managed Care Restrictions on Clinical Outcomes, Adherence/Persistence, Financial Outcomes, and Healthcare Resource Utilization in Neurological Conditions: A Systematic Literature Review (P1.366)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Evaluation of the Impact of Managed Care Restrictions on Clinical Outcomes, Adherence/Persistence, Financial Outcomes, and Healthcare Resource Utilization in Neurological Conditions: A Systematic Literature Review (P1.366)
- Open Access
- 22 May 2013
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 19 (6) , 619-631
The Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial Fibrillation
The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been recently indicated for stroke prevention in patients with atrial fibrillation (AF) . Due to a lack of direct head-to-head trials comparing the NOACs, the current systematic review and network meta-analysis (NMA) were conducted to assess their relative efficacy and safety. Three phase III randomized controlled trials enrolling 50 578 patients were included. Results of the NMA show a clear trend favoring NOACs over warfarin with regard to the key outcomes of stroke/systemic embolism and all-cause mortality, with apixaban also showing a favorable response for major bleeding and total discontinuations. Although there were few significant differences among the NOACS with regard to efficacy outcomes, apixaban and dabigatran 110 mg were associated with significantly lower hazards of major bleeding compared with dabigatran 150 mg and rivaroxaban. The NOACs offer a therapeutic advance over standard warfarin treatment in stoke prevention in patients with nonvalvular AF.
- 22 May 2013
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 19 (6) , 619-631
Open AccessThe Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial Fibrillation
The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been recently indicated for stroke prevention in patients with atrial fibrillation (AF) . Due to a lack of direct head-to-head trials comparing the NOACs, the current systematic review and network meta-analysis (NMA) were conducted to assess their relative efficacy and safety. Three phase III randomized controlled trials enrolling 50 578 patients were included. Results of the NMA show a clear trend favoring NOACs over warfarin with regard to the key outcomes of stroke/systemic embolism and all-cause mortality, with apixaban also showing a favorable response for major bleeding and total discontinuations. Although there were few significant differences among the NOACS with regard to efficacy outcomes, apixaban and dabigatran 110 mg were associated with significantly lower hazards of major bleeding compared with dabigatran 150 mg and rivaroxaban. The NOACs offer a therapeutic advance over standard warfarin treatment in stoke prevention in patients with nonvalvular AF.